Clinical Trials Directory

Trials / Unknown

UnknownNCT04042662

Predictors and Outcomes of Meropenem Treatment Failure Among Patients With Septic Shock in Intensive Care Unit

Status
Unknown
Phase
Study type
Observational
Enrollment
400 (estimated)
Sponsor
Universiti Sains Malaysia · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Lately, the inappropriate used of Meropenem in critically ill patient were increased. Therefore, increased development of drug resistance bacteria towards Meropenem. As known that Carbapenem-Resistance Enterobacteriaceae (CRE) is part of complication when Meropenem is widely used in the intensive care unit. CRE are very difficult to treat within Gram negative bacteria as it encodes Carbapenemase enzyme which breaks down Carbapenem anti-microbial such as Meropenem. The widespread carbapenemase production in the Enterobacteriaceae was unknown until the early 2000 until first reported in 2001. Despite that, most doctors and physician favourite, and still prescribe Meropenem as the antibiotic of choice for the critically ill patients empirically. This is because of its broad spectrum of coverage for bacteria. Thus, a number of Meropenem treatment failure were increased as resistance increase.This study will evaluate the appropriate use of Meropenem and determine the predictors of Meropenem treatment failure as well as the patient outcomes.As a result, it can be a guidance prior prescribing the Meropenem base on patient clinical condition and parameters while balancing the risk and benefits of its used.

Conditions

Interventions

TypeNameDescription
OTHERno interventionno intervention

Timeline

Start date
2019-08-05
Primary completion
2020-08-05
Completion
2020-08-05
First posted
2019-08-02
Last updated
2019-08-02

Source: ClinicalTrials.gov record NCT04042662. Inclusion in this directory is not an endorsement.